# Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma

> **NCT06956716** · PHASE1,PHASE2 · RECRUITING · sponsor: **Zhejiang University** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Intrahepatic Cholangiocarcinoma

## Interventions

- **BIOLOGICAL:** individualized anti-tumor new antigen iNeo-Vac-R01 injection
- **DRUG:** Gemcitabine + cisplatin (GP)
- **DRUG:** Sintilimab injection

## Key facts

- **NCT ID:** NCT06956716
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-09
- **Primary completion:** 2027-04-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06956716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06956716, "Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06956716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*